Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 151 The United Laboratories International Holdings Limited Annual Report 2025 Name of subsidiaries Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2025 2024 珠海聯邦生物醫藥有限公司 (Note c) The PRC RMB92,320,000 100% 100% Sale, production, research and development of pharmaceutical products in the PRC Henan Lianmu Veterinary Medicine Co., Ltd. (Note c) The PRC RMB225,000,000 60% 60% Manufacturing and sale of veterinary drugs in the PRC Kendor Technology (Zhejiang) Co., Ltd. (Note b) The PRC RMB20,500,000 100% 100% Manufacturing and sale of medical device in the PRC The United Animal Healthcare (Zhuhai) Co., Ltd (Note c) The PRC RMB187,000,000 100% 100% Manufacturing and sale of veterinary drugs in the PRC 廣州聯新健康產業有限公司 (Note c) The PRC RMB5,000,000 100% 100% Trading of health products in the PRC Inner Mongolia United Everbright Biotechnology Co., Ltd (Note c) The PRC RMB68,356,000 100% 100% Manufacturing and sale of pharmaceutical intermediate Products in the PRC Notes: (a) Other than The United Laboratories (Hong Kong) Holding Limited, all subsidiaries are indirectly held by the Company. (b) A wholly foreign-owned enterprise established in the PRC. (c) A company established in the PRC with limited liability. (d) A joint stock limited liability company established in the PRC. The above table lists the subsidiaries of the Group which, in the opinion of the directors of the Company, principally affected the results or assets of the Group. To give details of other subsidiaries would, in the opinion of the directors, result in particulars of excessive length. 41. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY (Continued)